The head of a Seattle biotech company that recently introduced a new test that screens women for early signs of breast cancer says Angelina Jolie could have postponed or even avoided having a double mastectomy. The actress announced this week that she had both of her breasts surgically removed because she has a gene that puts her at high risk of developing breast cancer.
“I was quite upset,” Steven Quay, MD, said was his reaction when he first learned about Jolie’s mastectomies. Quay is the founder and CEO of Atossa Genetics (NASDAQ: ATOS), which in January launched a new diagnostic test called ForeCYTE that can spot pre-cancerous cells in breast fluid.
“I cannot speak for her medical care because I do not know all the details. I have to assume she has the best physicians money can buy,” Quay told American News Report. “But I think at least at a minimum, the ForeCYTE test, which shows what is actually going on in the breast on the day that you do the test, I think that test should have been part of the mix that physicians and the patient used in making the decision they made. They may have ended up in the same spot, but it’s an incredibly valuable piece of information.”
Writing in the New York Times, Jolie revealed that she had both breasts removed in February even though she had not been diagnosed with breast cancer. Jolie is at high risk of developing breast and ovarian cancer because she has the BRAC1 gene.
Read more at American News Report.